Inclisiran by Novartis may be priced lower than other drugs targeting LDL cholesterol. Now that ICER has released its pricing report, the next question is: what will Novartis do? that keeping inclisiran cost-effective is a serious consideration.
“In our recent Evidence Report, ICER concluded that inclisiran (Novartis) can substantially lower LDL cholesterol, and we recommended a health-benefit price benchmark price of between $3,600 and $6,000 per year. Inclisiran’s cholesterol-lowering ability is similar to that demonstrated by the PCSK9 inhibitors Praluent and Repatha — two treatments that were launched with annual prices above $14,000, faced significant payer pushback for multiple years, and eventually saw price reductions toward ICER’s recommended range.” Read more about the ICER report here.
(Source: Angus Liu, Fierce Pharma, 1/29/21)